158 related articles for article (PubMed ID: 11877053)
21. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
22. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
25. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
[TBL] [Abstract][Full Text] [Related]
26. [Peripheral blood stem cell transplantation for 53 patients with malignant hematologic diseases].
Xie XS; Wan DM; Sun H; Sun L; Liu LX; Jiang ZX
Ai Zheng; 2007 Apr; 26(4):403-6. PubMed ID: 17430661
[TBL] [Abstract][Full Text] [Related]
27. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
[TBL] [Abstract][Full Text] [Related]
29. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
Terakura S; Wake A; Inamoto Y; Murata M; Sakai R; Yamaguchi T; Takahashi S; Uchida N; Onishi Y; Ohashi K; Ozawa Y; Kanamori H; Yamaguchi H; Fukuda T; Ichinohe T; Takanashi M; Atsuta Y; Teshima T
Bone Marrow Transplant; 2017 Mar; 52(3):423-430. PubMed ID: 27941766
[TBL] [Abstract][Full Text] [Related]
30. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
31. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
[TBL] [Abstract][Full Text] [Related]
32. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
[TBL] [Abstract][Full Text] [Related]
33. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
[TBL] [Abstract][Full Text] [Related]
34. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
Kasper C; Sayer HG; Mügge LO; Schilling K; Scholl S; Issa MC; Höffken K
Bone Marrow Transplant; 2004 Jan; 33(1):65-9. PubMed ID: 14704658
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
36. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
[TBL] [Abstract][Full Text] [Related]
37. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
[TBL] [Abstract][Full Text] [Related]
38. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors.
Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2003 Nov; 32(9):881-7. PubMed ID: 14561988
[TBL] [Abstract][Full Text] [Related]
39. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
Nash RA; Antin JH; Karanes C; Fay JW; Avalos BR; Yeager AM; Przepiorka D; Davies S; Petersen FB; Bartels P; Buell D; Fitzsimmons W; Anasetti C; Storb R; Ratanatharathorn V
Blood; 2000 Sep; 96(6):2062-8. PubMed ID: 10979948
[TBL] [Abstract][Full Text] [Related]
40. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
